Krystal Biotech Inc (NASDAQ:KRYS) — Market Cap & Net Worth
Market Cap & Net Worth: Krystal Biotech Inc (KRYS)
Krystal Biotech Inc (NASDAQ:KRYS) has a market capitalization of $9.22 Billion ($9.22 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2362 globally and #867 in its home market, demonstrating a 4.16% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Krystal Biotech Inc's stock price $341.12 by its total outstanding shares 29479756 (29.48 Million). See Krystal Biotech Inc (KRYS) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Krystal Biotech Inc Market Cap History: 2017 to 2026
Krystal Biotech Inc's market capitalization history from 2017 to 2026. Data shows growth from $310.13 Million to $10.06 Billion (47.86% CAGR).
Index Memberships
Krystal Biotech Inc is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$935.64 Billion | 0.99% | #20 of 30 |
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.37% | #47 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.02% | #269 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.54% | #31 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.60 Trillion | 0.36% | #13 of 602 |
Weight: Krystal Biotech Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Krystal Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Krystal Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
18.68x
Krystal Biotech Inc's market cap is 18.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
35.48x
Krystal Biotech Inc's market cap is 35.48 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $612.59 Million | $1.03 Million | -$10.89 Million | 596.48x | N/A |
| 2023 | $3.66 Billion | $50.70 Million | $10.93 Million | 72.14x | 334.55x |
| 2024 | $4.62 Billion | $290.51 Million | $89.16 Million | 15.90x | 51.80x |
| 2025 | $7.27 Billion | $389.13 Million | $204.83 Million | 18.68x | 35.48x |
Competitor Companies of KRYS by Market Capitalization
Companies near Krystal Biotech Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Krystal Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Krystal Biotech Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Krystal Biotech Inc's market cap moved from $310.13 Million to $ 10.06 Billion, with a yearly change of 47.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.06 Billion | +38.36% |
| 2025 | $7.27 Billion | +57.37% |
| 2024 | $4.62 Billion | +26.28% |
| 2023 | $3.66 Billion | +56.60% |
| 2022 | $2.34 Billion | +13.25% |
| 2021 | $2.06 Billion | +16.58% |
| 2020 | $1.77 Billion | +8.34% |
| 2019 | $1.63 Billion | +166.51% |
| 2018 | $612.59 Million | +97.53% |
| 2017 | $310.13 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Krystal Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.22 Billion USD |
| MoneyControl | $9.22 Billion USD |
| MarketWatch | $9.22 Billion USD |
| marketcap.company | $9.22 Billion USD |
| Reuters | $9.22 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystro… Read more